US 2015/0306115 A1 · PREVENTION OR TREATMENT AGENT FOR HEPATIC FIBROSIS

Abstract

CBP/β-catenin inhibitor shows a superior defibrosing effect for Cre/loxP/HCV-MxCre transgenic mouse which is an animal experiment model of hepatic fibrosis, and useful as a prophylactic or therapeutic drug for hepatic fibrosis.

Claims8

Dependent claims

1-9. (canceled)

Dependencies are inferred from the claim text.

Facts

Application

14/651,789Filed 12 Dec 2013

Priority

JP 2012-27098712 Dec 2012

Published

29 Oct 2015

Term ends

Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 31/675
Phosphorus compounds: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/53
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having six-membered rings with three nitrogens as the only ring hetero…
A61K 31/5365
Having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines: ortho- or peri-condensed with…
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…

Prevention or treatment agent for hepatic fibrosis

Life of this patent

Abstract

Claims8

Prevention or treatment agent for hepatic fibrosis

Life of this patent

Abstract

Claims8